The quote you highlight points to the future but the future is now. Specials demand in multiple cancer types has already been established and that will grow rapidly with approval. This seems to be the rather obvious reason for placing murcidencel on the NHS high priced medicines list for cancer indication and not just GBM. IFRs and Cancer Fund reimbursement will be the gatekeepers. Patients paying out of pocket within or outside of the Specials Program will likely provide a per patient profit benefit and have priority scheduling until an acceptable agreement with NICE comes along. Best wishes.
Market Data 
Markets 
